Lucira Health Stock Forecast, Price & News

Lucira Health (NASDAQ:LHDX) Frequently Asked Questions

Is Lucira Health a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucira Health in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Lucira Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LHDX, but not buy additional shares or sell existing shares.
View analyst ratings for Lucira Health or view top-rated stocks.

Are investors shorting Lucira Health?

Lucira Health saw a decline in short interest in December. As of December 31st, there was short interest totaling 473,000 shares, a decline of 44.9% from the December 15th total of 858,700 shares. Based on an average trading volume of 279,300 shares, the days-to-cover ratio is presently 1.7 days. Approximately 1.7% of the company's stock are sold short.
View Lucira Health's Short Interest.

When is Lucira Health's next earnings date?

Lucira Health is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for Lucira Health.

How were Lucira Health's earnings last quarter?

Lucira Health, Inc. (NASDAQ:LHDX) released its earnings results on Thursday, November, 11th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.04. The firm had revenue of $14.98 million for the quarter, compared to analyst estimates of $18 million. Lucira Health had a negative trailing twelve-month return on equity of 43.84% and a negative net margin of 230.43%.
View Lucira Health's earnings history.

What guidance has Lucira Health issued on next quarter's earnings?

Lucira Health updated its fourth quarter 2021 earnings guidance on Thursday, December, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $30 M-, compared to the consensus revenue estimate of $28.40 million.

What price target have analysts set for LHDX?

3 Wall Street analysts have issued 12-month price targets for Lucira Health's stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Lucira Health's share price to reach $9.00 in the next year. This suggests a possible upside of 50.5% from the stock's current price.
View analysts' price targets for Lucira Health or view top-rated stocks among Wall Street analysts.

Who are Lucira Health's key executives?

Lucira Health's management team includes the following people:

• Mr. Erik T. Engelson, Pres, CEO & Director (Age 61, Pay $369.69k)
• Dr. Debkishore Mitra Ph.D., CTO & Director (Age 34, Pay $311.35k)
• Ms. Kelly Lewis Brezoczky, Exec. VP of Commercialization, Regulatory, Clinical & Bus. Devel. (Age 57, Pay $360.21k)
• Mr. Daniel V. George, CFO & Treasurer (Age 51)
• Mr. Hansgregory Charles Hartmann, Chief Operating Officer (Age 63)
• Greg Chodaczek, Investor Relations
• Mr. Kevin Walter Collins, Chief Revenue Officer
• Ms. Tamanna Prashar, VP of Global Supply Chain, Operations & Quality (Age 40)

Who are some of Lucira Health's key competitors?

Some companies that are related to Lucira Health include Meridian Bioscience (VIVO), Alpha Teknova (TKNO), OncoCyte (OCX), Quotient (QTNT), MyMD Pharmaceuticals (MYMD), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), Aspira Women's Health (AWH), Achieve Life Sciences (ACHV), ImmuCell (ICCC), Biomerica (BMRA), Navidea Biopharmaceuticals (NAVB), ARCA biopharma (ABIO), Trinity Biotech (TRIB) and StageZero Life Sciences (SZLSF).
View all of LHDX's competitors.

When did Lucira Health IPO?

(LHDX) raised $125 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. BofA Securities, William Blair and LifeSci Capital acted as the underwriters for the IPO.

What is Lucira Health's stock symbol?

Lucira Health trades on the NASDAQ under the ticker symbol "LHDX."

Who are Lucira Health's major shareholders?

Lucira Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Cutler Group LP (0.00%).
View institutional ownership trends for Lucira Health.

Which major investors are selling Lucira Health stock?

LHDX stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Lucira Health or view top insider-selling stocks.

How do I buy shares of Lucira Health?

Shares of LHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lucira Health's stock price today?

One share of LHDX stock can currently be purchased for approximately $5.98.

How much money does Lucira Health make?

Lucira Health has a market capitalization of $234.57 million and generates $270 thousand in revenue each year.

How many employees does Lucira Health have?

Lucira Health employs 57 workers across the globe.

What is Lucira Health's official website?

The official website for Lucira Health is www.lucirahealth.com.

Where are Lucira Health's headquarters?

Lucira Health is headquartered at 1412 62ND STREET, EMERYVILLE CA, 94608.

How can I contact Lucira Health?

Lucira Health's mailing address is 1412 62ND STREET, EMERYVILLE CA, 94608. The company can be reached via phone at 510-350-8071.